scout
|Videos|July 13, 2020

Radioiodine Refractory Differentiated Thyroid Carcinoma

A key opinion leader discusses the evolving treatment landscape for radioiodine refractory differentiated thyroid carcinoma, with special consideration of the phase 3 SELECT trial.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME